Healthcare / BiotechnologyKOSDAQ
$2460.00
-125.00 (-4.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-1.7B · quality 41.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$31.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-21.6%
↓Gross Margin
39.9%
↓Debt/Equity
1.10
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.7%
FCF CAGR
—
FCF margin
-13.2%
FCF / Net income
0.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $12.90B · net income $-3.30B · FCF $-1.70B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $12.90B | $12.90B | $11.14B | $10.47B | $10.63B |
| Net Income | $-3.30B | $-3.30B | $-7.95B | $-2.86B | $2.70B |
| EBITDA | $-735.3M | $-735.3M | $-7.31B | $-3.90B | $3.55B |
| EPS | -275.00 | -275.00 | -870.00 | -313.00 | 119.00 |
| Gross Margin | 39.9% | 39.9% | 36.0% | 30.7% | 29.3% |
| Operating Margin | -27.1% | -27.1% | -37.0% | -45.5% | -46.4% |
| Net Margin | -25.6% | -25.6% | -71.4% | -27.3% | 25.4% |
| Balance Sheet | |||||
| Debt/Equity | 1.10 | 1.10 | 2.48 | 1.02 | 0.79 |
| Current Ratio | 0.49 | 0.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.70B | $-1.70B | $-4.29B | $25.0M | $-9.32B |
| Returns | |||||
| ROE | -21.6% | -21.6% | -164.4% | -21.4% | 16.7% |
| Valuation | |||||
| P/E | — | — | — | — | 34.12 |
| EV/EBITDA | — | — | — | — | 13.73 |
| P/B | 1.93 | 1.93 | 3.96 | 3.01 | 2.29 |
| Growth & Yield | |||||
| Revenue Growth | 15.8% | 15.8% | 6.3% | -1.5% | — |
| EPS Growth | 68.4% | 68.4% | -178.0% | -363.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+44.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-870.00 → -275.00
Residual
+44.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.